The Journal of Contemporary Dental Practice

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 23 , ISSUE 2 ( February, 2022 ) > List of Articles


Assessment of Electromyographic Changes in a Patient with Masseter Hypertrophy and Muscle Pain after Botulinum Injections: A Case Report and 5 Months Follow-up

Edoardo Bianco, Ruggero Tagliabue, Luca Mirabelli, Marcello Maddalone

Keywords : Botulinum toxin, Dental esthetics, Masseter, Occlusion, Orofacial pain, Sleep bruxism

Citation Information : Bianco E, Tagliabue R, Mirabelli L, Maddalone M. Assessment of Electromyographic Changes in a Patient with Masseter Hypertrophy and Muscle Pain after Botulinum Injections: A Case Report and 5 Months Follow-up. J Contemp Dent Pract 2022; 23 (2):226-231.

DOI: 10.5005/jp-journals-10024-3296

License: CC BY-NC 4.0

Published Online: 10-06-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Aim: To determine if botulinum injections in masseters could be an option to avoid surgery and prolonged treatment with occlusal splints and/or drugs to care for both painful bruxism and cosmetic improvement in a patient with a square jaw, bruxism, and orofacial pain. Background: Masseter muscle hypertrophy (MMH) is a benign, unilateral, or bilateral, painless enlargement in the lower face. It presents as a symmetrical or asymmetrical increase in the masseter muscle. Masseter muscle hypertrophy (MMH) sometimes can be related to bruxism symptoms like muscle and/or temporomandibular joint (TMJ) pain. Case description: A 38-year-old woman complained of bilateral pain at palpation in the masseter body. She also complained about esthetics because of the prominent masseter muscle in the face and square face shape. A diagnosis of bruxism-related myalgia was performed, and treatment with botulinum injections into the masseter muscles was opted for. An oral electromyography was performed to detect the electrical muscular activity of masseter muscles over time. Conclusion: After a drastic reduction in the mean electrical activity immediately after the botulinum injections, a progressive increase in strength over time was noted, testifying about the decrease in the effect of botulinum over time. The pain disappeared for 5 months after the injections of botulinum. The reduction of the masseter muscle mass led to a softening of the face shape. Clinical significance: This case report shows that treatment with botulinum can lead, in the short term, to a reduction in orofacial pain due to a decrease in muscle electrical activity.

  1. Quezada-Gaon N, Wortsman X, Peñaloza O, et al. Comparison of clinical marking and ultrasound-guided injection of Botulinum type A toxin into the masseter muscles for treating bruxism and its cosmetic effects. J Cosmet Dermatol 2016;15(3):238–244. DOI: 10.1111/jocd.12208.
  2. Bayrak NB, Zeybek M, Sanlioglu I, et al. Assessment of changes in masseter muscle by three-dimensional close-range photogrammetry after Botulinum toxin type-A injection: a case report with review of literature. J Pak Med Assoc 2019;69(3):418–422. PMID: 30890839.
  3. Fedorowicz Z, vanZuuren EJ, Schoones J. Botulinum toxin for masseter hypertrophy. Cochrane Database of Systematic Reviews 2013, Issue 9. Art. No.: CD007510. DOI: 10.1002/14651858.CD007510.pub3.
  4. Diracoglu D, Sahbaz T, Alptekin K, et al. Effects of ultrasound-assisted botulinum neurotoxin-A injection in patients with bruxism and masseter hypertrophy. Turk J Phys Med Rehabil 2021;67(3): 351–356. DOI: 10.5606/tftrd.2021.6288.
  5. Yap AU, Chua AP. Sleep bruxism: current knowledge and contemporary management. J Conserv Dent 2016;19(5):383–389. DOI: 10.4103/0972-0707.190007.
  6. Cortese M, Pigato G, Casiraghi G, et al. Evaluation of the oropharyngeal airway space in Class II malocclusion treated with mandibular activator: a retrospective study. J Contemp Dent Pract 2020;21(6): 666–672. PMID: 33025936.
  7. Manfredini D, Ahlberg J, Lobbezoo F. Bruxism definition: past, present, and future-what should a prosthodontist know? J Prosthet Dent 2021;S0022–3913(21)00074–3. DOI: 10.1016/j.prosdent.2021.01.026.
  8. Kaya DI, Ataoglu H. Botulinum toxin treatment of temporomandib ular joint pain in patients with bruxism: a prospective and randomized clinical study. Niger J Clin Pract 2021;24(3):412–417. DOI: 10.4103/njcp.njcp_251_20
  9. Bianco E, Nanussi A, Bellotti D, et al. Clinical and functional analyses of the musculoskeletal balance with oral electromyography and stabilometric platform in athletes of different disciplines. World J Dent 2020;11(3):166–171. DOI: 10.5005/jp-journals-10015-1722.
  10. Ham JW. Masseter muscle reduction procedure with radiofrequency coagulation. J Oral Maxillofac Surg 2009;67(2):457–463. DOI: 10.1016/j.joms.2006.04.012.
  11. Beckers HL. Masseteric muscle hypertrophy and its intraoral surgical correction. J Maxillofac Surg 1977;5(1):28–35. DOI: 10.1016/s0301-0503(77)80072-6.
  12. Nigam PK, Nigam A. Botulinum toxin. Indian J Dermatol 2010;55(1): 8–14. DOI: 10.4103/0019-5154.60343.
  13. Bhattacharjee K, Singh M, Bhattacharjee H. Extended effect after a single dose of type A botulinum toxin for asymmetric masseter muscle hypertrophy. Indian J Plast Surg 2015;48(2):196–199. DOI: 10.4103/0970-0358.163061
  14. Ferrario VF, Sforza C, Colombo A, et al. An electromyographic investigation of masticatory muscles symmetry in normo-occlusion subjects. J Oral Rehabil 2000;27(1):33–40. DOI: 10.1046/j.1365-2842.2000.00490.x.
  15. Maddalone M, Bianco E, Nanussi A, et al. Treatment of temporomandibular disorders of muscular origin with a silicon oral device (Alifix®): electromyographic analysis. J Contemp Dent Pract 2019;20(12):1367–1374. PMID: 32381834.
  16. Maddalone M, Nanussi A, Varisco M, et al. Electromyographic evaluation of masticatory muscles in a young patient with crossbite treated with rapid palatal expander: a case report. J Contemp Dent Pract 2020;21(11):1279–1283. PMID: 33850076.
  17. Beddis H, Pemberton M, Davies S. Sleep bruxism: an overview for clinicians. Br Dent J 2018;225(6):497–501. DOI: 10.1038/sj.bdj.2018.757.
  18. Ohrbach R (ed.). Diagnostic Criteria for Temporomandibular Disorders: Assessment Instruments. Version 15 May 2016.
  19. Cheng Y, Yuan L, Ma L, et al. Efficacy of botulinum-A for nocturnal bruxism pain and the occurrence of bruxism events: a meta-analysis and systematic review. Br J Oral Maxillofac Surg 2022;60(2):174–182. DOI: 10.1016/j.bjoms.2021.03.005.
  20. Frank AS. Masticatory muscle hyperactivity and temporomandibular joint dysfunction. J Prosthet Dent 1965;15(6):1122–1131. DOI: 10.1016/0022-3913(65)90188-5.
  21. Graziano P, Dell'Aversana Orabona G, Astarita F, et al. Bilateral hypertrophy of masseteric and temporalis muscles, our fifteen patients and review of literature. Eur Rev Med Pharmacol Sci 2016;20(1):7–11. PMID: 26813447.
  22. Dias R, Vaz R, Rodrigues MJ, et al. Utility of smartphone-based real-time report (Ecological Momentary Assessment) in the assessment and monitoring of awake bruxism: a multiple-week interval study in a Portuguese population of university students. J Oral Rehabil 2021;48(12):1307–1313. DOI: 10.1111/joor.13259.
  23. Lobbezoo F, van der Zaag J, van Selms MKA, et al. Principles for the management of bruxism. J Oral Rehab 2008;35(7):509–523. DOI: 10.1111/j.1365-2842.2008.01853.x.
  24. Jadhao VA, Lokhande N, Habbu SG, et al. Efficacy of botulinum toxin in treating myofascial pain and occlusal force characteristics of masticatory muscles in bruxism. Indian J Dent Res 2017;28(5):493–497. DOI: 10.4103/ijdr.IJDR_125_17.
  25. Azeez AA, Sherif S, Franca R. Statistical estimation of wear in permanent teeth: a systematic review. Dent Rev 2021;1(1).
  26. Mostafa D, Fatima N. Gingival recession and root coverage up to date: a literature review. Dent Rev 2021;1(1).
  27. Bilgin Çetin M, Sezgin Y, Maraş E, et al. Association of probable bruxism with periodontal status: a cross-sectional study in patients seeking periodontal care. J Periodontal Res 2021;56(2):370–378. DOI: 10.1111/jre.12829.
  28. D'Errico G, Bianco E, Tregambi E, et al. Usage of Lactobacillus reuteri DSM 17938 and ATCC PTA 5289 in the treatment of the patient with black stains. World J Dent 2021;12(1):32–37. DOI: 10.5005/jp-journals-10015-1800.
  29. Bianco E. Factors influencing immediate maxillary dental implant placement and bone resorption: a review of the literature and an outlook on the clinical possibilities. Dent Med Probl 2016;53(3): 408–412. DOI: 10.17219/dmp/63185.
  30. Bianco E, Calvelli C, Citterio CL, et al. Evaluation with micro-CT of the canal seal made with two different bioceramic cements: guttaflow bioseal and bioroot RCS. J Contemp Dent Pract 2020;21(4):359–366. PMID: 32584269.
  31. Scavia S, Roncucci R, Bianco E, et al. Minimal invasive flapless piezotome alveolar crest horizontal split technique: preliminary results. J Contemp Dent Pract 2020;21(1):28–35. PMID: 32381797.
  32. Marcello M, Luca M, Sara B, et al. Radiographic evaluation of the bone remodeling on tilted osseointegrated implants: follow-up at 1 year. J Contemp Dent Pract 2020;21(4):463–470. PMID: 32584287.
  33. Testut L. Anatomy of the face. In: Testut L, Jacob O (eds). Topographic Anatomy. Barcelona: Editores Salvat; 1981;2: pp. 223–33.
  34. Abraham S, Moideen F, Arunima PR, et al. Lip repositioning surgery–a boon in perioesthetics. Case Rep Dent Sci 3(1):35–46. PMID: 1845036.
  35. Hakam MM, Beheiry MG, Helmy ES. Surgical management of benign masseteric hypertrophy (B.M.H.). Egypt Dent J 1995;41(4):1435–1440. PMID: 9497694.
  36. Hashimoto T, Kuroda S, Kamioka H, et al. Bimaxillary protrusion with masseter muscle hypertrophy treated with titanium screw anchorage and masseter surgical reduction. Am J Orthod Dentofacial Orthop 2009;135(4):536–548. DOI: 10.1016/j.ajodo.2006.10.043.
  37. Huang J-L, Chen G, Chen X-D, et al. A comparative study of the efficacy and safety of radiofrequency ablation and botulinum toxin A in treating masseteric hypertrophy. Exp Ther Med 2014;7(5):1203–1208. DOI: 10.3892/etm.2014.1552.
  38. Shetty N, Malaviya RK, Gupta MK. Management of unilateral masseter hypertrophy and hypertrophic scar-a case report. Case Rep Dent 2012;2012:521427. DOI: 10.1155/2012/521427.
  39. Sendra LA, Montez C, Vianna KC, et al. Clinical outcomes of botulinum toxin type A injections in the management of primary bruxism in adults: a systematic review. J Prosthet Dent 2021;126(1):33–40. DOI: 10.1016/j.prosdent.2020.06.002.
  40. Kwon K-H, Shin KS, Yeon SH, et al. Application of botulinum toxin in maxillofacial field: part I. Bruxism and square jaw. Maxillofac Plast Reconstr Surg 2019;41(1):38. DOI:10.1186/s40902-019-0218-0.
  41. Ågren M, Sahin C, Pettersson M. The effect of botulinum toxin injections on bruxism: a systematic review. J Oral Rehabil 2020;47(3):395–402. DOI: 10.1111/joor.12914.
  42. Yurttutan ME, Tütüncüler Sancak K, Tüzüner AM. Which treatment is effective for bruxism: Occlusal splints or botulinum toxin? J Oral Maxillofac Surg 2019;77(12):2431–2438. DOI: 10.1016/j.joms.2019.06.005.
  43. Lee SJ, McCall WD, Kim YK, et al. Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial. Am J Phys Med Rehabil 2010;89(1):16–23. DOI: 10.1097/PHM.0b013e3181bc0c78.
  44. Wei J, Xu H, Dong J, et al. Prolonging the duration of masseter muscle reduction by adjusting the masticatory movements after the treatment of masseter muscle hypertrophy with botulinum toxin type a injection. Dermatol Surg 2015;41(Suppl 1):S101–S109. DOI: 10.1097/DSS.0000000000000162.
  45. Mathevon L, Michel F, Decavel P, et al. Muscle structure and stiffness assessment after botulinum toxin type A injection. A systematic review. Ann Phys Rehabil Med 2015;58(6):343–350. DOI: 10.1016/
  46. To EW, Ahuja AT, Ho WS, et al. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Br J Plat Surg 2001;54:197–200. DOI: 10.1054/bjps.2000.3526.
  47. Dover JS, Monheit G, Greener M, et al. Botulinum toxin in aesthetic medicine: myths and realities. Dermatol Surg 2018;44(2):249–260. DOI: 10.1097/DSS.0000000000001277.
  48. Pirazzini M, Rossetto O, Eleopra R, et al. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev 2017;69(2): 200–235. DOI: 10.1124/pr.116.012658.
  49. NIH Panel. Clinical Use of Botulinum Toxin. NIH Consens Statement, 1990 November 12–14;8(8):1–20.
  50. Lange O, Bigalke H, Dengler R, et al. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 2009;32(4): 213–218. DOI: 10.1097/WNF.0b013e3181914d0a.
  51. Naumann M, Carruthers A, Carruthers J, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord 2010;25(13): 2211–2218. DOI: 10.1002/mds.23254.
  52. Dressler D, Wohlfahrt K, Meyer-Rogge E, et al. Antibody-induced failure of botulinum toxin a therapy in cosmetic indications. Dermatol Surg 2010;36(Suppl 4):2182–2187. DOI: 10.1111/j.1524-4725.2010.01710.x.
  53. Kun-Darbois J-D, Libouban H, Chappard D. Botulinum toxin in masticatory muscles of the adult rat induces bone loss at the condyle and alveolar regions of the mandible associated with a bone proliferation at a muscle enthesis. Bone 2015;77:75–82. DOI: 10.1016/j.bone.2015.03.023.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.